-
Capital, M&A & Industry Strategy2 weeks agoCould OMass become the UK’s ‘big biotech’ company?
UK-based OMass Therapeutics' ambition to join the 'big biotech' ranks has been bolstered by an impressive $310m third-round financing.
-
Capital, M&A & Industry Strategy2 weeks agoGSK planning 1,200 job cuts in Belgium, says paper
GSK is said to be preparing to cut around 1,200 positions from its workforce in Belgium as part of a cost-saving programme launched by CEO Luke...
-
AI, Machine Learning & Computational Biology2 weeks agoZealand forges obesity alliance with AI specialist Generate
Zealand has added another strand to its programme of weight-loss drug development, linking with AI player Generate on multispecific protein therapies.
-
Global Biotechnology & Pharmaceutical Markets2 weeks agoSanofi escapes fine in EU mismarketing case
Sanofi will not be fined for disparaging an influenza vaccine sold by rival CSL in a marketing campaign, according to the European Commission.
-
Clinical Trials & Development3 weeks agoBioNTech sticks with cancer vaccine despite trial miss
BioNTech's vaccine for head and neck cancer has failed a clinical trial, but it will wait for more data before deciding the programme's fate.
-
Drug Discovery & Therapeutics3 weeks agoRoche adds another obesity drug with $1.16bn Rona deal
Roche has added to its weight-loss drug pipeline again, turning to China's Rona Therapeutics for an RNAi candidate targeting ALK7.
-
Capital, M&A & Industry Strategy3 weeks agoBambusa, Aspen, and Tang added to IPO pipeline
2026's sizeable haul of IPOs shows no signs of letting up, with three more biotechs – Bambusa, Aspen, and blank cheque firm Tang – joining the...
-
Regulatory Intelligence & Drug Approvals3 weeks agoAicuris acquisition delivers new drug for Asahi Kasei
Asahi Kasei's $920m takeover of Germany's Aicuris in April has paid off with FDA approval for the herpes simplex virus drug at the heart of the...
-
Drug Discovery & Therapeutics3 weeks agoIambic prices its IPO, seeking to raise up to $160m
AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.
-
Capital, M&A & Industry Strategy3 weeks agoMatchpoint scores $150m for I&I drugs, and other financings
Matchpoint has closed a $150m round for its immunology-focused covalent drugs, with KymaThera, Rouge, Sensible Bio, and Arboretum also raising funds.
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure
100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
